Is Perspective Therapeutics, Inc. (CATX) a Buy, Sell, or Hold?
AMEX : CATX
Perspective Therapeutics, Inc.
$2.95 USD
-$0.27 (-8.39%)
- Volume
- 1.38M
- Average Volume
- 1.86M
- Market Capitalization
- $227.89M
- P/E Ratio
- -0.12
- Dividend Yield
- 0.00%
- Price Target
- $12.00
- Year High
- $6.16
- Year Low
- $1.96
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.75
Industry, Sector & symbol
| Stock Exchange | AMEX |
| CEO | Johan Spoor |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Current Symbol | CATX |
| CUSIP | 46489V302 |
| CIK | 0000728387 |
| Web | https://www.perspectivetherapeutics.com |
| Phone | 509 375 1202 |
| Currency | USD |
| Employees | 166 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 8.75 |
| Quick Ratio | 8.75 |
| Cash Ratio | 1.71 |
Sales & Book Value
| Annual Sales | -$ |
| Price / Sales | 402.50 |
| Cash Flow | -103.59 |
| Price / Cash Flow | -2.32 |
| Price / Book | 0.01 |
Price Target and Rating
| Average Stock Price Forecast | $12.00 |
| High Stock Price Forecast | $16.00 |
| Low Stock Price Forecast | $12.00 |
| Forecast Upside/Downside | -75.42% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 11 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$1.4 |
| Trailing P/E Ratio | -0.12 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | -$103.12M |
| Net Margin | -17982.69% |
| Pretax Margin | -18194.17% |
| Return on Equity | -41.84% |
| Return on Assets | -27.05% |
Financials Score
| AltmanZ Score | 0.77 |
| Piotroski Score | 3.00 |
| Working Capital | 243.87M |
| Total Assets | 410.77M |
| Ebit | -114.28M |
| Market Cap | 232.52M |
| Total Liabilities | 63.33M |
Poll Results
About Perspective Therapeutics, Inc. (AMEX:CATX) Stock
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. Th ... e entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year?
2026-07-16 10:40:34
Here is how Perspective Therapeutics (CATX) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.
Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K.
2026-07-08 06:30:00
Dr. Lyne joins Perspective from Merck KGaA with more than 25 years in biopharmaceuticals and contributions to more than 30 oncology programs Dr. Lyne joins Perspective from Merck KGaA with more than 25 years in biopharmaceuticals and contributions to more than 30 oncology programs
Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial
2026-06-03 14:08:57
Perspective Therapeutics Inc. (NYSE-A:CATX) has treated the first patient with a type of brain tumor called meningioma using its experimental drug [212Pb]VMT-a-NET, broadening a clinical trial that previously focused only on a different cancer type known as neuroendocrine tumors. The new arm of the Phase 1/2a study, called LEMONaDE, aims to assess how safe the treatment is and whether it shows early signs of shrinking tumors in meningioma patients.
Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial
2026-06-03 10:06:00
Perspective Therapeutics Inc. (NYSE-A:CATX) has treated the first patient with a type of brain tumor called meningioma using its experimental drug...
2026-06-03 06:30:00
SEATTLE, June 03, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that the first meningioma patient was dosed with [212Pb]VMT-α-NET in the Company's ongoing Phase 1/2a study.
2026-05-21 17:51:00
SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updates on all three of its advancing clinical programs, [²¹²Pb]VMT-α-NET, [²¹²Pb]VMT01, and [²¹²Pb]PSV359, will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 29 to June 2, 2026 in Chicago, IL.
2026-05-18 06:30:00
SEATTLE, May 18, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that the first patients were dosed with [212Pb]VMT-α-NET and [212Pb]PSV359 in two new cohorts of Phase 1/2a studies in neuroendocrine tumors and solid tumors, respectively.
2026-05-13 20:00:53
Perspective Therapeutics, Inc. (CATX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Frequently Asked Questions
-
What is the current Perspective Therapeutics, Inc. (CATX) stock price?
-
Perspective Therapeutics, Inc.(AMEX:CATX) stock price is $2.95 in the last trading session. During the trading session, CATX stock reached the peak price of $6.16 while $1.96 was the lowest point it dropped to. The percentage change in CATX stock occurred in the recent session was --8.39% while the dollar amount for the price change in CATX stock was -$0.27.
-
CATX's industry and sector of operation?
-
The AMEX listed CATX is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of CATX?
-
Michael K. Schultz | Co-Founder & Senior Scientific Advisor
Paul Lyne | Chief Science Officer
Markus Puhlmann | Chief Medical Officer
Amos Hedt PGradDip | Chief Business Strategy Officer
Andrew Bright | Executive Vice President of Brachytherapy -
How many employees does CATX have?
-
Number of CATX employees currently stands at 166. CATX operates from 350 Hills Street, Seattle, WA 99354, US.
-
Link for CATX official website?
-
Official Website of CATX is: https://www.perspectivetherapeutics.com
-
How do I contact CATX?
-
CATX could be contacted at phone #509 375 1202 and can also be accessed through its website. CATX operates from 350 Hills Street, Seattle, WA 99354, US.
-
How many shares of CATX are traded daily?
-
The average number of CATX shares traded daily for last 3 months was 1.86M.
-
What is the market cap of CATX currently?
-
The market value of CATX currently stands at $227.89M with its latest stock price at $2.95